February 15, 2017
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
February 5, 2017
Here's a closer look at last week's top gainers.
December 19, 2016
Editas Medicine, a leading genome editing company, today announced it has exclusively licensed intellectual property related to new CRISPR technologies...
March 10, 2016
Editas Medicine's share price went on a tear following its IPO in February. In the last two days, however, it's...